1,2-di-O-hexadecyl-rac-glycero-3-phosphonoxy propylamine | 65848-09-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 甘油磷脂
• 英文名称: 1,2-di-O-hexadecyl-rac-glycero-3-phosphonoxy propylamine
• 英文别名: 3-Azaniumylpropyl 2,3-dihexadecoxypropyl phosphate；3-azaniumylpropyl 2,3-dihexadecoxypropyl phosphate
• CAS: 65848-09-1
• 化学式: C₃₈H₈₀NO₆P
• 分子量: 678.03
• InChiKey: YUWBXOVGWGIXMN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  11.4
• 重原子数：
  46
• 可旋转键数：
  40
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  100
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  phosphoric acid 2,3-bis-hexadecyloxy-propyl ester 3-bromo-propyl ester 在 氨 作用下， 以 氯仿 、 异丙醇 、 乙腈 为溶剂， 生成 1,2-di-O-hexadecyl-rac-glycero-3-phosphonoxy propylamine
  参考文献：
  名称：

  Nuhn; Rueger; Kertscher, Pharmazie, 1978, vol. 33, # 4, p. 181 - 183

  摘要：

  DOI：

文献信息

• A Lipid-Lipase Aggregate with Ether Linkage as a New Type of Immobilized Enzyme for Enantioselective Hydrolysis in Organic Solvents.
  作者：Hiroyuki AKITA、Isao UMEZAWA、Hiroko MATSUKURA、Takeshi OISHI

  DOI：10.1248/cpb.40.318

  日期：——

  For the purpose of carrying out smoothly enzymatic reaction of water-insoluble substrates in organic solvents, a new type of immobilized enzyme, a lipid-lipase aggregate, was developed. In order to prepare various kinds of lipid-lipase aggregates, 27 kinds of dialkyl ether-type phospholipid analogues were newly synthesized and used for the preparation of aggregates with lipase. Thus obtained lipid-lipase aggregates were found to catalyze the enantioselective hydrolysis of the (±)-α-acyloxy ester 2 much more efficiently than lipase immobilized with synthetic prepolymer (ENTP-4000) in water-saturated isopropyl ether. Namely. the reaction time became much shorter (2 to 3d for completion as compared with 21 d) and the chemical and optical yields of the reaction products were found to be high.

  为了顺利进行水不溶性底物在有机溶剂中的酶促反应，开发了一种新型的固定化酶——脂质-脂肪酶聚集体。为了制备各种脂质-脂肪酶聚集体，新合成了27种二烷基醚型磷脂类似物，并用于制备与脂肪酶的聚集体。所得的脂质-脂肪酶聚集体被发现能够比在水分饱和的异丙醚中通过合成预聚物（ENTP-4000）固定的脂肪酶更有效地催化（±）-α-酰氧基酯2的对映选择性水解。即，反应时间大大缩短（完成需要2至3天，而之前需要21天），并且反应产物的化学和光学产率都很高。
• [EN] COMPOSITIONS AND METHODS FOR DELIVERY OF THERAPEUTIC AGENTS<br/>[FR] COMPOSITIONS ET PROCÉDÉS PERMETTANT D'ADMINISTRER DES AGENTS THÉRAPEUTIQUES
  申请人：MODERNATX INC

  公开号：WO2017099823A1

  公开（公告）日：2017-06-15

  This disclosure provides improved lipid-based compositions, including lipid nanoparticle compositions, and methods of use thereof for delivering agents in vivo including nucleic acids and proteins. These compositions are not subject to accelerated blood clearance and they have an improved toxicity profile in vivo.

  这项披露提供了改进的基于脂质的组合物，包括脂质纳米粒子组合物，以及它们用于体内传递药剂的方法，包括核酸和蛋白质。这些组合物不受加速血清清除的影响，并且它们在体内具有改进的毒性特性。
• COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS
  申请人：ModernaTX, Inc.

  公开号：US20180028664A1

  公开（公告）日：2018-02-01

  This disclosure provides improved lipid-based compositions, including lipid nanoparticle compositions, and methods of use thereof for delivering agents in vivo including nucleic acids and proteins. These compositions are not subject to accelerated blood clearance and they have an improved toxicity profile in vivo.
• [EN] POLYNUCLEOTIDES ENCODING α-GALACTOSIDASE A FOR THE TREATMENT OF FABRY DISEASE<br/>[FR] POLYNUCLÉOTIDES CODANT POUR L'Α-GALACTOSIDASE A POUR LE TRAITEMENT DE LA MALADIE DE FABRY
  申请人：MODERNATX INC

  公开号：WO2017201328A1

  公开（公告）日：2017-11-23

  The invention relates to mRNA therapy for the treatment of Fabry disease. mRNAs for use in the invention, when administered in vivo, encode human the α-galactosidase A (GLA), isoforms thereof, functional fragments thereof, and fusion proteins comprising GLA. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of GLA expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient GLA activity in subjects, namely Gb3 and lyso-Gb3.
• [EN] POLYNUCLEOTIDES ENCODING PORPHOBILINOGEN DEAMINASE FOR THE TREATMENT OF ACUTE INTERMITTENT PORPHYRIA<br/>[FR] POLYNUCLÉOTIDES CODANT POUR LA PORPHOBILINOGÈNE DÉSAMINASE DESTINÉS AU TRAITEMENT DE LA PORPHYRIE INTERMITTENTE AIGUË
  申请人：MODERNATX INC

  公开号：WO2017201346A1

  公开（公告）日：2017-11-23

  The invention relates to mRNA therapy for the treatment of Acute Intermittent Porphyria (AIP). mRNAs for use in the invention, when administered in vivo, encode human porphobilinogen deaminase (PBGD), isoforms thereof, functional fragments thereof, and fusion proteins comprising PBGD. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to affect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of PBGD expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient PBGD activity in subjects, namely porphobilinogen and aminolevulinate (PBG and ALA).